Similar outcomes were reported by the French Group on Lung Cancer (GFPC) [22] in patients who had received one previous treatment, and in the IMMUNOTARGET registry, where smoker patients with HER2-mutant NSCLC exhibited a significantly longer median PFS compared with nonsmokers (3.4 months vs. 2.0 months, p = 0.04) [23]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.